Cargando…

HDL and glucose metabolism: current evidence and therapeutic potential

High-density lipoprotein (HDL) and its principal apolipoprotein A-I (ApoA-I) have now been convincingly shown to influence glucose metabolism through multiple mechanisms. The key clinically relevant observations are that both acute HDL elevation via short-term reconstituted HDL (rHDL) infusion and c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Siebel, Andrew L., Heywood, Sarah Elizabeth, Kingwell, Bronwyn A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2015
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4628107/ https://www.ncbi.nlm.nih.gov/pubmed/26582989 http://dx.doi.org/10.3389/fphar.2015.00258

Ejemplares similares

MicroRNA-194 Modulates Glucose Metabolism and Its Skeletal Muscle Expression Is Reduced in Diabetes
por: Latouche, Celine, et al.
Publicado: (2016)

HDL in sepsis – risk factor and therapeutic approach
por: Morin, Emily E., et al.
Publicado: (2015)

Identification of Docetaxel as a Potential Drug to Promote HDL Biogenesis
por: Choi, Hong Y., et al.
Publicado: (2021)

Antioxidant properties of HDL
por: Soran, Handrean, et al.
Publicado: (2015)

HDL-S1P: cardiovascular functions, disease-associated alterations, and therapeutic applications
por: Levkau, Bodo
Publicado: (2015)

Pharmacological Intervention to Modulate HDL: What Do We Target?
por: Woudberg, Nicholas J., et al.
Publicado: (2018)

HDL as a drug and nucleic acid delivery vehicle
por: Lacko, Andras G., et al.
Publicado: (2015)

Sodium, Glucose and Dysregulated Glucagon Secretion: The Potential of Sodium Glucose Transporters
por: Armour, Sarah L., et al.
Publicado: (2022)

Mini Review: Current Trends and Understanding of Exosome Therapeutic Potential in Corneal Diseases
por: Tiwari, Anil, et al.
Publicado: (2021)

HDL particle number and size as predictors of cardiovascular disease
por: Kontush, Anatol
Publicado: (2015)

Protective Effects of HDL Against Ischemia/Reperfusion Injury
por: Gomaraschi, Monica, et al.
Publicado: (2016)

The Role of HDL and HDL Mimetic Peptides as Potential Therapeutics for Alzheimer’s Disease
por: Chernick, Dustin, et al.
Publicado: (2020)

Insulin-induced mTOR signaling and gluconeogenesis in renal proximal tubules: A mini-review of current evidence and therapeutic potential
por: Nakamura, Motonobu, et al.
Publicado: (2022)

Frequent interruptions of sedentary time modulates contraction- and insulin-stimulated glucose uptake pathways in muscle: Ancillary analysis from randomized clinical trials
por: Bergouignan, Audrey, et al.
Publicado: (2016)

The Therapeutic Potential of Anthocyanins: Current Approaches Based on Their Molecular Mechanism of Action
por: Salehi, Bahare, et al.
Publicado: (2020)

Synergetic Effect of rHDL and LXR Agonist on Reduction of Atherosclerosis in Mice
por: Morin, Emily E., et al.
Publicado: (2020)

Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives
por: Sarkar, Chandan, et al.
Publicado: (2020)

Reconstituted HDL: Drug Delivery Platform for Overcoming Biological Barriers to Cancer Therapy
por: Raut, Sangram, et al.
Publicado: (2018)

Current state of phoenixin—the implications of the pleiotropic peptide in stress and its potential as a therapeutic target
por: Friedrich, T., et al.
Publicado: (2023)

I(f) Channel as an Emerging Therapeutic Target for Cardiovascular Diseases: A Review of Current Evidence and Controversies
por: Mengesha, Hayelom G., et al.
Publicado: (2017)

Therapeutic Applications of Human and Bovine Colostrum in the Treatment of Gastrointestinal Diseases and Distinctive Cancer Types: The Current Evidence
por: Bagwe-Parab, Siddhi, et al.
Publicado: (2020)

Potential therapeutic effects and pharmacological evidence of sinomenine in central nervous system disorders
por: Hong, Hongxiang, et al.
Publicado: (2022)

HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis
por: Chyu, Kuang-Yuh, et al.
Publicado: (2015)

The Kappa Opioid Receptor: A Promising Therapeutic Target for Multiple Pathologies
por: Dalefield, Martin L., et al.
Publicado: (2022)

Fasting Plasma Glucose, Self-Appraised Diet Quality and Depressive Symptoms: A US-Representative Cross-Sectional Study
por: Hoare, Erin, et al.
Publicado: (2017)

HDL Phospholipids, but Not Cholesterol Distinguish Acute Coronary Syndrome From Stable Coronary Artery Disease
por: Meikle, Peter J., et al.
Publicado: (2019)

An appraisal of the current status of inhibition of glucose transporters as an emerging antineoplastic approach: Promising potential of new pan-GLUT inhibitors
por: Temre, Mithlesh Kumar, et al.
Publicado: (2022)

Editorial: Therapeutic potential of natural products-based drugs in regulation of lipid metabolism
por: Rašković, Aleksandar, et al.
Publicado: (2023)

Sex-Specific Associations in Nutrition and Activity-Related Risk Factors for Chronic Disease: Australian Evidence from Childhood to Emerging Adulthood
por: Hoare, Erin, et al.
Publicado: (2018)

Caveolin-1 Regulates Cellular Metabolism: A Potential Therapeutic Target in Kidney Disease
por: Luo, Shilu, et al.
Publicado: (2021)

hnRNP A1 in RNA metabolism regulation and as a potential therapeutic target
por: Feng, Jianguo, et al.
Publicado: (2022)

HDL as a Biomarker, Potential Therapeutic Target, and Therapy
por: Navab, Mohamad, et al.
Publicado: (2009)

Current clinical evidence on pioglitazone pharmacogenomics
por: Kawaguchi-Suzuki, Marina, et al.
Publicado: (2013)

Therapeutic Potential of Polyphenol and Nanoparticles Mediated Delivery in Periodontal Inflammation: A Review of Current Trends and Future Perspectives
por: Jayusman, Putri Ayu, et al.
Publicado: (2022)

Recurrent Oral Cancer: Current and Emerging Therapeutic Approaches
por: da Silva, Sabrina Daniela, et al.
Publicado: (2012)

Therapeutic Potential of Targeting ß-Arrestin
por: Bond, Richard A., et al.
Publicado: (2019)

The Current Status of Research on High-Density Lipoproteins (HDL): A Paradigm Shift from HDL Quantity to HDL Quality and HDL Functionality
por: Cho, Kyung-Hyun
Publicado: (2022)

Cardiotoxicity of Cancer Therapeutics: Current Issues in Screening, Prevention, and Therapy
por: Sheppard, Richard J., et al.
Publicado: (2013)

Can Positive Framing Reduce Nocebo Side Effects? Current Evidence and Recommendation for Future Research
por: Barnes, Kirsten, et al.
Publicado: (2019)

Palmitoylethanolamide (PEA) as a Potential Therapeutic Agent in Alzheimer’s Disease
por: Beggiato, Sarah, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_a6qsesag487tdvd24bm52vhlcr